Nagehan ERDOĞMUŞ KÜÇÜKCAN, Akif KÜÇÜKCAN

COVID-19 ile enfekte hastalarda koku ve tat disfonksiyonu prevalansı

Amaç: Bu çalışma, COVID-19 ile enfekte kişilerin hastaneye başvuru şekline ve olası risk faktörlerine göre koku ve tat alma disfonksiyonunu (KTD) değerlendirmeyi amaçlamaktadır. Gereç ve Yöntem: Çalışmaya Ocak ve Eylül 2021 arasında COVID-19 tanısı konan toplam 200 hasta dahil edildi. Hastalar iki gruba ayrıldı. İlk grupta; kliniği daha hafif seyreden, evde izole olan 100 hasta, ikinci grupta; kliniği daha ağır seyreden pandemi servisinde yatan 100 hasta bulunmaktaydı. Hastalar hastaneye başvuru sırasında koku ve tat fonksiyonları ve çeşitli klinik bilgileri hakkında veri formu doldurdu. Hastalardan ayrıca görsel analog skalası (GAS) kullanarak koku ve tat bozukluklarını derecelendirmeleri istendi. Bulgular: Evde izole olarak takip edilen hastaların, %72’ si kadın olup, yaş ortalaması 39,6±13,2’dır. Pandemi servisinde takip edilen hastaların ise %50’ si kadın ve ortalama yaş 52.4±11,0. Tüm hastalarda en sık görülen semptom tat (%41) ve koku (45,5) kaybıydı. Kadın cinsiyette ve gençlerde KTD daha yüksek bulundu. Ayaktan hastalarda KTD daha sıktı. Tat ve koku VAS skorları ayakta takip edilen hastalarda daha düşüktü. Sonuç: KTD; COVID-19 ile enfekte kişilerde çeşitli mekanizmalar aracılığıyla artmış inflamatuar yanıta bağlı oluşur. KTD, anahtar semptom ve tanı göstergesi olarak görülmeli ve sorgulanmalıdır. KTD sıklığının yaş gruplarında ve cinsiyete göre farklılıklar gösterebileceği akılda tutulmalıdır.

Prevalence of smell and taste dysfunction in patients infected with COVID-19

Purpose: This study aims to evaluate olfactory and gustatory dysfunctions (OGDs) in COVID-19 patients according to hospital admission type and possible risk factors for OGD. Materials and Methods: This study included 200 adult patients who were diagnosed with COVID-19 between January 2021 and September 2021. Patients were separated into two groups. The first group comprised 100 patients who applied to pandemic outpatient clinics with a milder course and were isolated at home. The second group comprised 100 patients with a more severe clinical course hospitalized in the pandemic ward. Patients completed a data form in which olfactory and gustatory functions and various clinical information were inquired about and rated their smell and taste dysfunction using a visual analog scale (VAS). Results: In the ambulatory group, 72% of patients were female and the mean age was 39.6±13.2 years. In the admitted group, 50% of patients were female, and the mean age was 52.4±11.0 years. The most common symptoms in all patients were loss of taste (41%) and smell (45.5%). Females and younger individuals were significantly more likely to have OGD. OGD was more common in the ambulatory group. Smell/taste VAS scores were significantly lower in the ambulatory group. Conclusion: OGD is associated with various mechanisms depending on the increased inflammatory response in the early stages of COVID-19. OGD appears to be the key symptom and diagnostic indicator and should be inquired about. It should be kept in mind that the frequency of OGD may differ according to age and gender.

PDF

___

1. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708-20.
2. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. 2020;277:2251-61.
3. Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A et al. Objective evaluation of anosmia and ageusia in COVID‐19 patients: single‐center experience on 72 cases. Head Neck. 2020;42:1252-58.
4. Gane SB, Kelly C, Hopkins C. Isolated sudden onset anosmia in COVID-19 infection. A novel syndrome. Rhinology. 2020;58:299-301.
5. Vaira LA, Salzano G, Deiana G, De Riu G. Anosmia and ageusia: common findings in COVID‐19 patients. Laryngoscope. 2020;130:1787-87.
6. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:1-5.
7. Han AY, Mukdad L, Long JL, Lopez IA. Anosmia in COVID-19: mechanisms and significance. Chem Senses. 2020;45:423-28.
8. Milanetti E, Miotto M, Di Rienzo L, Nagaraj M, Monti M, Golbek TW et al. In-silico evidence for a two receptor based strategy of SARS-CoV-2. Front Mol Biosci. 2021;8:
9. Altin F, Cingi C, Uzun T, Bal C. Olfactory and gustatory abnormalities in COVID-19 cases. Eur Arch Otorhinolaryngol. 2020;277:2775-81.
10. Welge-Lüssen A, Wolfensberger M. Olfactory disorders following upper respiratory tract infections. Taste and Smell. 2006;63:125-32.
11. Whitcroft KL, Hummel T. Olfactory dysfunction in COVID-19: diagnosis and management. JAMA. 2020;323:2512-14.
12. Agyeman AA, Chin KL, Landersdorfer CB, Liew D, Ofori-Asenso R. Smell and taste dysfunction in patients with COVID-19: a systematic review and meta-analysis. Mayo Clin Proc. 2020;95:1621-31.
13. Moein ST, Hashemian SM, Mansourafshar B, Khorram‐Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID‐19. Int Forum Allergy Rhinol. 2020;10:944-50.
14. Klopfenstein T, Kadiane-Oussou N, Toko L, Royer P-Y, Lepiller Q, Gendrin V et al. Features of anosmia in COVID-19. Med Mal Infect. 2020;50:436-9.
15. Özçelik KM, Eğilmez OK, Özçelik MA, Güven M. Otolaryngological manifestations of hospitalised patients with confirmed COVID-19 infection. Eur Arch Otorhinolaryngol. 2021;278:1675-85.
16. Meini S, Suardi LR, Busoni M, Roberts AT, Fortini A. Olfactory and gustatory dysfunctions in 100 patients hospitalized for COVID-19: sex differences and recovery time in real-life. Eur Arch Otorhinolaryngol. 2020;277:3519-23.
17. Al-Rawi NH, Sammouda AR, AlRahin EA, Ali FAA, Arayedh GSA, Daryanavard HA, et al. Prevalence of anosmia or ageusia in patients with COVID-19 among United Arab Emirates population. Int Dent J. 2022;72:249-56.
18. Yan CH, Faraji F, Prajapati DP, Ostrander BT, DeConde AS. Self‐reported olfactory loss associates with outpatient clinical course in COVID‐19. Int Forum Allergy Rhinol. 2020;10:821-31.
19. Al-Ani RM, Acharya D. Prevalence of anosmia and ageusia in patients with COVID-19 at a primary health center, Doha, Qatar. Indian J Otolaryngol Head Neck Surg. 2020; doi: 10.1007/s12070-020-02064.
20. Lee Y, Min P, Lee S, Kim SW. Prevalence and duration of acute loss of smell or taste in COVID-19 patients. J Korean Med Sci. 2020;35:e174.
21. Zayet S, Klopfenstein T, Mercier J, Kadiane-Oussou NJ, Lan Cheong Wah L, Royer PY et al. Contribution of anosmia and dysgeusia for diagnostic of COVID19 in outpatients. Infection. 2021;49:361-5.
22. Kavaz E, Tahir E, Bilek HC, Kemal Ö, Deveci A, Aksakal Tanyel E. Clinical significance of smell and taste dysfunction and other related factors in COVID19. Eur Arch Otorhinolaryngol. 2021;278:2327-36.
23. Vaira LA, Hopkins C, Salzano G, Petrocelli M, Melis A, Cucurullo M et al. Olfactory and gustatory function impairment in COVID‐19 patients: Italian objective multicenter‐study. Head Neck. 2020;42:1560-9.
24. D’Ascanio L, Pandolfini M, Cingolani C, Latini G, Gradoni P, Capalbo M et al. Olfactory dysfunction in COVID-19 patients: prevalence and prognosis for recovering sense of smell. Otolaryngol Head Neck Surg. 2021;164:82-6.
25. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497- 506.
26. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061-9.